Interestingly, metformin treatment significantly increased protein levels of Cu/ZnSOD and decreased MnSOD levels in kidneys but did not alter GST-P levels in Ob-NAFLD + M rats compared to L + M or Ob-NAFLD groups (Figure 5E–H). The gene discussed is SOD2; the disease is metabolic dysfunction-associated steatotic liver disease.